Efficacy and Circuit Mechanisms of Noninvasive Brain-Computer Interface Therapy for Upper-Extremity Motor Function in Patients With Ischemic Stroke
NCT07924683, Not applicable, Not yet recruiting, Xuanwu Hospital, Beijing
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy and Circuit Mechanisms of Noninvasive Brain-Computer Interface Therapy for Upper-Extremity Motor Function in Patients With Ischemic Stroke | ClinicalTrials.gov |
| NCT number | NCT07924683 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 38 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Xuanwu Hospital, Beijing | ClinicalTrials.gov |
| Conditions | Stroke, Rehabilitation, Brain Computer Interface | ClinicalTrials.gov |
| Interventions | BCI system together with the active-passive exoskeleton training system | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The difference between the FMA-UE score at the end of treatment and the baseline FMA-UE score | Day 90 after training. | The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. | ClinicalTrials.gov |
| Secondary | The difference between the Action Research Arm Test (ARAT) at the end of treatment and the baseline. | Day 90 after training. | The Action Research Arm Test (ARAT) total score ranges from 0 to 57, with higher scores indicating better upper-extremity functional ability. | ClinicalTrials.gov |
| Secondary | The difference between the Motor Status Scale (MSS) at the end of treatment and the baseline. | Day 90 after training. | The Motor Status Scale (MSS) total score ranges from 0 to 82, with higher scores indicating better upper-extremity motor function. | ClinicalTrials.gov |
| Secondary | The difference between the Stroke-Specific Quality of Life Scale (SS-QOL) at the end of treatment and the baseline. | Day 90 after training. | The Stroke-Specific Quality of Life Scale (SS-QOL) total score ranges from 49 to 245, with higher scores indicating better stroke-specific quality of life. | ClinicalTrials.gov |
| Secondary | The difference between Stroke Rehabilitation Motivation Scale, 7-item version (SRMS-7) at the end of treatment and the baseline. | Day 90 after training. | The Stroke Rehabilitation Motivation Scale, 7-item version (SRMS-7), total score ranges from 7 to 35, with higher scores indicating greater rehabilitation motivation. | ClinicalTrials.gov |
| Secondary | The difference between Apathy Evaluation Scale-Selfrated (AES-S) at the end of treatment and the baseline. | Day 90 after training. | The Apathy Evaluation Scale-Self-rated (AES-S) total score ranges from 18 to 72, with higher scores indicating greater apathy and a worse outcome. | ClinicalTrials.gov |
| Secondary | The difference between Temporal Experience of Pleasure Scale (TEPS) at the end of treatment and the baseline. | Day 90 after training. | The Temporal Experience of Pleasure Scale (TEPS) total score ranges from 18 to 108, with higher scores indicating greater pleasure and less anhedonia. | ClinicalTrials.gov |
| Secondary | The difference between Hamilton Anxiety Rating Scale (HAMA) at the end of treatment and the baseline. | Day 90 after training. | The Hamilton Anxiety Rating Scale (HAMA) total score ranges from 0 to 56, with higher scores indicating greater anxiety severity and a worse outcome. | ClinicalTrials.gov |
| Secondary | The difference between Hamilton Depression Rating Scale (HAMD) at the end of treatment and the baseline. | Day 90 after training. | The 17-item Hamilton Depression Rating Scale (HAMD-17) total score ranges from 0 to 52, with higher score. | ClinicalTrials.gov |
| Secondary | The difference between fMRI/sMRI measures of structural and functional brain changes at the end of treatment and the baseline. | Day 90 after training. | EEG and fNIRS measures depend on the prespecified electrophysiological or hemodynamic metric. | ClinicalTrials.gov |
| Secondary | The difference between EEG and functional near-infrared spectroscopy (fNIRS) measures at the end of treatment and the baseline, including decoding accuracy, cortical activation, and brain-network topology | Day 90 after training. | EEG and fNIRS measures depend on the prespecified electrophysiological or hemodynamic metric. | ClinicalTrials.gov |
| Other | Incidence of Adverse events | From baseline through the Day 90 follow-up visit. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)